Abstract: A method of forming a semiconductor device includes providing a substrate having a recess, and growing an epitaxial feature in the recess. The method of growing the epitaxial feature includes: (a) growing a sub-layer of the epitaxial feature; (b) selectively etching the sub-layer of the epitaxial feature while providing a first UV radiation; and (c) repeating step (a) and step (b) alternately multiple times.

Abstract: A manufacturing method for a LED is disclosed. The method includes: providing a substrate with an upper surface; preparing a plurality of LEDs on the upper surface; wherein the upper surface is divided into a plurality of zones, the plurality of LEDs composes a plurality of LED groups, and each of the LED group is disposed in one of the plurality of zones; preparing a testing circuit to electrically connecting the plurality of LEDs in one of the plurality of LED groups; testing the plurality of LEDs in the one of the plurality of LED groups by the testing circuit to obtain photoelectrical characteristics of the plurality of LEDs in the one of the plurality of LED groups; and presenting the photoelectric characteristics in an image.

Abstract: The present invention relates to a method for preparing a modified stem cell, including the following steps: a cell culture step: culturing stem cells in a first culture medium of a culture dish at a predetermined cell density, and removing the first culture medium after a first culture time to obtain a first cell intermediate; an activity stimulation step: preserving the first cell intermediate in a freezing container having a cell cryopreservation solution, and performing a constant temperature stimulation treatment or a variable temperature stimulation treatment for at least more than 1 day; and a product collection step: after completing the activity stimulation step, placing the freezing container in an environment at a thawing temperature for thawing, and then removing the cell cryopreservation solution to obtain the modified stem cell. The modified stem cell can release at least one or more of IL-4, IL-5, IL-13, G-CSF, Fractalkine, and EGF.

Abstract: A stacked package structure and a manufacturing method thereof are provided. The stacked package structure includes an upper redistribution layer, a first chip, and an upper molding layer. The first chip is disposed on the upper redistribution layer and is electrically connected to the upper redistribution layer. The upper molding layer is disposed on the first chip and the upper redistribution layer, and is configured to package the first chip. The upper molding layer includes a recess, the recess is recessed relative to a surface of the upper molding layer away from the upper redistribution layer, and the recess is circumferentially formed around a periphery of the upper molding layer.

Abstract: A semiconductor light emitting device includes a multi-quantum-well structure, a first capping layer, a second capping layer, and an electron barrier layer stacked in order. The multi-quantum-well structure includes a plurality of alternately-stacked potential barrier layers and potential well layers. The first capping layer is a semiconductor layer, and the second capping layer is a p-doped semiconductor layer. Each of the first and second capping layers has an aluminum mole fraction larger than that of each of the potential barrier layers, and the aluminum mole fraction of the first capping layer is larger than that of at least a portion of the electron barrier layer. A method for preparing the semiconductor light emitting device is also provided.

Abstract: An optical system affixed to an electronic apparatus is provided, including a first optical module, a second optical module, and a third optical module. The first optical module is configured to adjust the moving direction of a first light from a first moving direction to a second moving direction, wherein the first moving direction is not parallel to the second moving direction. The second optical module is configured to receive the first light moving in the second moving direction. The first light reaches the third optical module via the first optical module and the second optical module in sequence. The third optical module includes a first photoelectric converter configured to transform the first light into a first image signal.

Abstract: A method for predicting clinical severity of a neurological disorder includes steps of: a) identifying, according to a magnetic resonance imaging (MRI) image of a brain, brain image regions each of which contains a respective portion of diffusion index values of a diffusion index, which results from image processing performed on the MRI image; b) for one of the brain image regions, calculating a characteristic parameter based on the respective portion of the diffusion index values; and c) calculating a severity score that represents the clinical severity of the neurological disorder of the brain based on the characteristic parameter of the one of the brain image regions via a prediction model associated with the neurological disorder.

Abstract: The present disclosure relates to a method for inhibiting a binding of a SARS-CoV-2 spike protein of a SARS-CoV-2 to an angiotensin-converting enzyme 2 including contacting the SARS-CoV-2 with a sufficient concentration of disulfiram, a method for inhibiting an activity of a main protease (Mpro) of SARS-CoV-2 including contacting a SARS-CoV-2 with a sufficient concentration of disulfiram, and a method for inhibiting an activity of a papain-like protease (PLpro) of SARS-CoV-2 including contacting a SARS-CoV-2 with a sufficient concentration of disulfiram. A method for inhibiting a replication or an infection of a SARS-CoV-2 in a cell includes contacting the cell with a sufficient concentration of disulfiram and a medical composition for use in a treatment of an infection of SARS-CoV-2 including a therapeutically effective amount of disulfiram are also provided.

Abstract: The present disclosure relates to a method for preventing or inhibiting a synthesis of viral RNA of SARS-CoV-2 in a cell including contacting the cell with a sufficient concentration of tafenoquine, boceprevir or narlaprevir and a method for inhibiting an activity of a main protease (Mpro) of SARS-CoV-2 including contacting a SARS-CoV-2 with a sufficient concentration of tafenoquine, boceprevir or narlaprevir. A medical composition for use in a treatment of an infection of SARS-CoV-2 including a therapeutically effective amount of tafenoquine, boceprevir or narlaprevir is also provided.

Abstract: Pharmaceutical compositions containing a combination of anti-chondrogenesis agents are disclosed. Methods of reducing scleral chondrogensis, reducing one or more ocular chondrogenic proteins, reducing inflammation induced chondrogensis and treating myopia by administering an effective amount of one or more anti-chondrogensis agents are also provided. The pharmaceutical compositions are useful for treating myopia.

Abstract: Pharmaceutical compositions containing a combination of anti-chondrogenesis agents are disclosed. Methods of reducing scleral chondrogensis, reducing one or more ocular chondrogenic proteins, reducing inflammation induced chondrogensis and treating myopia by administering an effective amount of one or more anti-chondrogensis agents are also provided. The pharmaceutical compositions are useful for treating myopia.

Abstract: Pharmaceutical compositions containing a combination of anti-chondrogenesis agents are disclosed. Methods of reducing scleral chondrogenesis, reducing one or more ocular chondrogenic proteins, reducing inflammation induced chondrogenesis and treating myopia by administering an effective amount of one or more anti-chondrogenesis agents are also provided. The pharmaceutical compositions are useful for treating myopia.

Abstract: Pharmaceutical compositions containing a combination of anti-chondrogenesis agents are disclosed. Methods of reducing scleral chondrogenesis, reducing one or more ocular chondrogenic proteins, reducing inflammation induced chondrogenesis and treating myopia by administering an effective amount of one or more anti-chondrogenesis agents are also provided. The pharmaceutical compositions are useful for treating myopia.

Abstract: Pharmaceutical compositions containing a combination of anti-chondrogenesis agents are disclosed. Methods of reducing scleral chondrogensis, reducing one or more ocular chondrogenic proteins, reducing inflammation induced chondrogensis and treating myopia by administering an effective amount of one or more anti-chondrogensis agents are also provided. The pharmaceutical compositions are useful for treating myopia.

Abstract: A method is provided for securely delivering identity data units over a communications network to a client device. The method includes receiving a selection from a customer identifying a final zipped package to be unpacked. The final zipped package is unpacked to obtain a common package and a digital signature file signed by an entity generating identity data requested by the customer. The digital signature in the digital signature file is verified and the common package is unpacked to obtain a plurality of outer packages and an encrypted symmetric key. The symmetric key is decrypted with a private key associated with the customer and each of the outer packages is decrypted with the symmetric key to obtain a plurality of identity data units.

Abstract: A method and apparatus is provided for maintaining inventory levels of identity data to be provisioned in electronic devices. The method includes monitoring over a communications network inventory levels of identity data records stored on a plurality of identity data personalization servers that each provision electronic devices with an identity data record. Additionally, if the inventory level on at least one of the identity data personalization servers falls below a minimum specified level, a refill request is sent to an identity data management authority requesting that additional identity data records be uploaded to the identity data personalization server.

Abstract: A method and apparatus are provided for generating identity data to be provisioned in product devices that are a part of a project. The method includes establishing a template associated with each CA in a hierarchical chain of CAs having a root CA at a highest level in the chain and a signing CA at a lowest level in the chain. The template associated with the signing CA inherits mandatory attribute fields specified in the root CA and any intermediate CA in the hierarchical chain. The mandatory attribute fields are user-specifiable fields to be populated with PKI data. A configuration file is generated upon receipt of an order for digital certificates using PKI data provided by a user to populate the mandatory attribute fields of the template associated with the signing CA. The digital certificates requested in the order are generated using the PKI data in the configuration file.

Abstract: A method is provided for securely delivering identity data units over a communications network to a client device. The method includes receiving a selection from a customer identifying a final zipped package to be unpacked. The final zipped package is unpacked to obtain a common package and a digital signature file signed by an entity generating identity data requested by the customer. The digital signature in the digital signature file is verified and the common package is unpacked to obtain a plurality of outer packages and an encrypted symmetric key. The symmetric key is decrypted with a private key associated with the customer and each of the outer packages is decrypted with the symmetric key to obtain a plurality of identity data units.

Abstract: A method and apparatus is provided for establishing a process for provisioning a digital certificate service delivered by a PKI system. The method includes receiving a request for a digital certificate service and receiving data specifying a project that includes at least one product to be provisioned with a digital certificate. Data specifying an identification of an owner organization of the project and at least one participant organization participating in the project is also received. Attributes with which PKI data to be included in the digital certificates is to comply is received from the owner organization. Based on the received data and attributes, an account is established for each of the organizations associated with the project through which users associated with each of the organizations can respectively request digital certificates for the at least one product in accordance with the attributes received from the owner organization.

Abstract: A method and apparatus are provided for generating identity data to be provisioned in product devices that are a part of a project. The method includes establishing a template associated with each CA in a hierarchical chain of CAs having a root CA at a highest level in the chain and a signing CA at a lowest level in the chain. The template associated with the signing CA inherits mandatory attribute fields specified in the root CA and any intermediate CA in the hierarchical chain. The mandatory attribute fields are user-specifiable fields to be populated with PKI data. A configuration file is generated upon receipt of an order for digital certificates using PKI data provided by a user to populate the mandatory attribute fields of the template associated with the signing CA. The digital certificates requested in the order are generated using the PKI data in the configuration file.